2026-05-04T19:32:47Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/205192024-11-28T19:28:36Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16966

00925njm 22002777a 4500 dc Perez-Garcia, Covadonga author Sempere, Julio author Miguel, Sara de author Hita, Samantha author Úbeda, Aída author Vidal-Alcántara, Erick Joan author Llorente, Joaquín author Limia, Aurora author Gil-de-Miguel, Ángel author Sanz, Juan Carlos author Martinón-Torres, Federico author Ardanuy, Carmen author Domenech Lucas, Mirian author Yuste, Jose Enrique author 2024-06-19 Objectives: Dynamic trends of invasive pneumococcal disease (IPD) including the evolution of prevalent serotypes are very useful to evaluate the impact of current and future pneumococcal conjugate vaccines (PCVs) and the rise of non-vaccine serotypes. In this study, we include epidemiological patterns of S. pneumoniae before and after COVID-19 pandemic. Methods: We characterized all national IPD isolates from children and adults received at the Spanish Pneumococcal Reference Laboratory during 2019-2023. Results: In the first pandemic year 2020, we found a general reduction in IPD cases across all age groups, followed by a partial resurgence in children in 2021 but not in adults. By 2022, IPD cases in children had returned to pre-pandemic levels, and partially in adults. In 2023, IPD rates surpassed those of the last pre-pandemic year. Notably, the emergence of serotype 3 is of significant concern, becoming the leading cause of IPD in both pediatric and adult populations over the last two years (2022-2023). Increase of serotype 4 in young adults occurred in the last epidemiological years. Conclusions: The COVID-19 pandemic led to a temporary decline in all IPD cases during 2020 attributable to non-pharmaceutical interventions followed by a subsequent rise. Employing PCVs with broader coverage and/or enhanced immunogenicity may be critical to mitigate the marked increase of IPD. J Infect. 2024 Jun 19;89(2):106204. 10.1016/j.jinf.2024.106204 1532-2742 The Journal of infection 38906265 http://hdl.handle.net/20.500.12105/20519 S. pneumoniae IPD COVID-19 PCVs Serotype 3 Serotype 4 Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023)